Granted Patent
B2
US 12,714,755 · App. 17/760,715 · Granted Aug 25, 2026
Effective dosages of an adenoviral-based biological delivery and expression system for use in the treatment of osteoarthritis in humans, and compositions comprising the same
View Patent ↗
Loading inventors, assignments & file history…
Assignments (5)
RELEASE OF SECURITY INTEREST
Recorded Dec 5, 2025
From: JPMORGAN CHASE BANK, N.A.
To: PACIRA CRYOTECH, INC.; PACIRA PHARMACEUTICALS, INC.; PACIRA THERAPEUTICS, INC. (F/K/A FLEXION THERAPEUTICS, INC.)
Reel/Frame 073779/0532 →
SECURITY INTEREST
Recorded Jul 4, 2025
From: PACIRA THERAPEUTICS, INC.
To: WELLS FARGO BANK, NATIONAL ASSOCIATION, AS ADMINISTRATIVE AGENT
Reel/Frame 071609/0342 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Mar 31, 2023
From: KELLEY, SCOTT; SENTER, REBECCA; CHABICOVSKY, MONIKA; MARTIN, EMILY WALSH; BODICK, NEIL; HONG, WON; WANG, KRIS; DOUGLAS, MARK; JACKSON, JOHN DEREK
To: FLEXION THERAPEUTICS, INC.
Reel/Frame 063195/0112 →
CHANGE OF NAME
Recorded Mar 31, 2023
From: FLEXION THERAPEUTICS, INC.
To: PACIRA THERAPEUTICS, INC.
Reel/Frame 063231/0187 →
CONFIRMATORY GRANT OF SECURITY INTEREST IN UNITED STATES PATENTS
Recorded Mar 31, 2023
From: PACIRA CRYOTECH, INC.; PACIRA PHARMACEUTICALS, INC.; PACIRA THERAPEUTICS, INC. (F/K/A FLEXION THERAPEUTICS, INC.)
To: JPMORGAN CHASE BANK, N.A.
Reel/Frame 063214/0108 →
Continuity (3)
Provisional Application
62966632
· Jan 28, 2020
Provisional Application
62902041
· Sep 18, 2019
References Cited (222)
US 5747072A
· Davidson et al.
· 1998
[cited by applicant]
US 5919676A
· Graham et al.
· 1999
[cited by applicant]
US 6083750A
· Chamberlain et al.
· 2000
[cited by applicant]
US 6743774B1
· Jay
· 2004
[cited by applicant]
US 6890528B1
· Colloca
· 2005
[cited by applicant]
US 7419808B2
· Zhang et al.
· 2008
[cited by applicant]
US 8877445B2
· Shackney
· 2014
[cited by applicant]
US 20010006948A1
· Kang et al.
· 2001
[cited by applicant]
US 20020081719A1
· Massaad
· 2002
[cited by applicant]
US 20020099024A1
· Wickham et al.
· 2002
[cited by applicant]
US 20020146392A1
· Graham et al.
· 2002
[cited by applicant]
US 20030091536A1
· Frisbee et al.
· 2003
[cited by applicant]
US 20030104626A1
· Fallaux et al.
· 2003
[cited by applicant]
US 20040072741A1
· Jay
· 2004
[cited by applicant]
US 20050260596A1
· Fallaux et al.
· 2005
[cited by applicant]
US 20080019975A1
· Gorman
· 2008
[cited by applicant]
US 20080038233A1
· Freemont et al.
· 2008
[cited by applicant]
US 20090023196A1
· Fallaux et al.
· 2009
[cited by applicant]
US 20090104148A1
· Jay et al.
· 2009
[cited by applicant]
US 20090274688A1
· Boyle et al.
· 2009
[cited by applicant]
US 20100215731A1
· Emans et al.
· 2010
[cited by applicant]
US 20100254937A1
· Han
· 2010
[cited by applicant]
US 20100255572A1
· Schmidt et al.
· 2010
[cited by applicant]
US 20120045764A1
· Grompe
· 2012
[cited by applicant]
US 20130102028A1
· Chun et al.
· 2013
[cited by applicant]
US 20150031083A1
· Lee
· 2015
[cited by examiner]
US 20150118187A1
· Shapir et al.
· 2015
[cited by applicant]
US 20150232836A1
· Krieg
· 2015
[cited by applicant]
US 20150361452A1
· Ruan et al.
· 2015
[cited by applicant]
US 20160304572A1
· Schmidt et al.
· 2016
[cited by applicant]
US 20190350968A1
· Erwin
· 2019
[cited by applicant]
US 20190376080A1
· Lee et al.
· 2019
[cited by applicant]
US 20220073948A1
· Lee et al.
· 2022
[cited by applicant]
US 20220348963A1
· Lee et al.
· 2022
[cited by applicant]
US 20230158170A1
· Senter
· 2023
[cited by applicant]
US 20240102049A1
· Ruan et al.
· 2024
[cited by applicant]
EP 0832267B1
· 2002
[cited by applicant]
EP 0821739B1
· 2003
[cited by applicant]
EP 2298925
· 2011
[cited by applicant]
WO WO02082908
· 2002
[cited by applicant]
WO WO05016130
· 2005
[cited by applicant]
WO WO05085421
· 2005
[cited by applicant]
WO WO07002261
· 2007
[cited by applicant]
WO WO08143816
· 2008
[cited by applicant]
WO WO10052505
· 2010
[cited by applicant]
WO WO10135736
· 2010
[cited by applicant]
WO WO10138939
· 2010
[cited by applicant]
WO WO13114199
· 2013
[cited by applicant]
WO WO14115022
· 2014
[cited by applicant]
WO WO17191274
· 2017
[cited by applicant]
WO WO20132226
· 2020
[cited by applicant]
WO WO0046360
· 2020
[cited by applicant]
WO WO22241228
· 2022
[cited by applicant]
U.S. Department of Health and Human Services Food and Drug Administration 2016, Recommendations for Microbial Vectors used for Gene Therapy: Guidance for Industry, 1-27. (Year: 2016).
[cited by examiner]
Gallaher & Berk 2013, J. Virol. Methods, 192(0), 28-38. (Year: 2013).
[cited by examiner]
Roamer & Sharov 2019, BioProcess International, retrieved on Apr. 25, 2025 from the Internet: <https://www.bioprocessintl.com/sponsored-content/qualitative-and-quantitative-host-cell-protein-analysis-using-mass-spectrom…
[cited by examiner]
Puntel et al. 2006, Human Gene Therapy, 17, 531-544. (Year: 2006).
[cited by examiner]
Roessler et al. 1995, Human Gene Therapy, 6, 307-316. (Year: 1995).
[cited by examiner]
Takahashi et al. 2006, Analytical Biochemistry, 349, 208-217. (Year: 2006).
[cited by examiner]
Vellekamp et al. 2001, Human Gene Therapy, 12, 1923-1936. (Year: 2001).
[cited by examiner]
Johnson 2018, Comments submitted by PDA for Docket ID: FDA-2008-D-0205, PDA, 1-10. (Year: 2018).
[cited by examiner]
NCBI 2010,
[cited by examiner]
Benneker et al., 2005, 2004 Young investigator award winner: vertebral endplate marrow contact channel occlusions and intervertebral disc degeneration, Spine, 30(2):167-173.
[cited by applicant]
Bibby et al., 2004, Effect of nutrient deprivation on the viability of intervertebral disc cells, Eur Spine J. 13:695-701.
[cited by applicant]
Brooks, 2002, Impact of osteoarthritis on individuals and society: how much disability? Social consequences and health economic implications. Curr Opin Rheumatol, 14:573-577.
[cited by applicant]
Dolan et al., 2001, An EMG technique for measuring spinal loading during asymmetric lifting, Clin. Biomech. 16(Supplement 1):S17-S24.
[cited by applicant]
Dolan et al., 2001, Recent advanced in lumbar spinal mechanics and their significance for modelling, Clin.Biomech. 16(Supplement 1):S8-S16.
[cited by applicant]
Eskola et al., 2012, Gender difference in genetic association between IL1A variant and early lumbar disc degeneration: a three-year follow-up, Int J Mol Epidemiol Genet. 3(3):195-204.
[cited by applicant]
Gruber et al., 1998, Analysis of aging and degeneration of the human intervertebral disc, Spine, 23(7):751-757.
[cited by applicant]
Heathfield et al., 2008, Caveolin-1 expression and stress-induced premature senescence in human intervertebral disc degeneration, Arthritis Res.Ther., 10(4):1-9.
[cited by applicant]
Hoyland et al., 2008, Investigation of the role of IK-1 and TNF in matrix degradation in the intervertebral disc, Rheumatology, 47:809-814.
[cited by applicant]
Hunter et al., Sep. 2011, Emerging drugs for osteoarthritis, Expert Opin. Emerging Drugs, 16(3):479-491.
[cited by applicant]
Inkinen et al., Relative increase of biglycan and decorin and altered chondroitin sulfate epitopes in the degenerating human intervertebral disc, The Journal of Rheumatology, 25(3):506-514.
[cited by applicant]
Le Maetre et al., 2021, Development of a standardized histopathology scoring system for human intervertebral disc degeneration: an Orphopaedic Research Society Spine Section initiative, JOR Spine, 4:e1167.
[cited by applicant]
Le Maitre et al., 2005, The role of interleukin-1 in the pathogenesis of human intervertebral disc degeneration, Arthritis Res Ther. 7:R732-R745.
[cited by applicant]
Le Maitre et al., 2004, Localization of degradative enzymes and their inhibitors in the degenerate human intervertebral disc, J Pathol. 204:47-54.
[cited by applicant]
Le Maitre et al., 2006, A preliminary in vitro study into the use of IL-1Ra gene therapy for the inhibition of intervertebral disc degeneration, Int J Exp Pathol. 87:17-28.
[cited by applicant]
Le Maitre et al., 2007, Matrix synthesis and degradation in human intervertebral disc degeneration, Arthritis Res Ther., 35(4):652-655.
[cited by applicant]
Luoma et al., 2000, Low back pain in relation to lumbar disc degeneration, Spine, 25(4):487-492.
[cited by applicant]
Mwale et al., 2004, Distinction between the extracellular matrix of the nucleus pulposus and hyaline cartilage: a requisite for tissue engineering of intervertebral disc, European Cells and Materials, 8:58-64.
[cited by applicant]
Palmer et al., 2003, Improved system for helper-dependent adenoviral vector production. Mol Ther 8:846-852.
[cited by applicant]
Paz Aparicio et al., 2011, The IL-1? (+3953 T/C) gene polymorphism associates to symptomatic lumbar disc herniation, Eur Spine J., 29(Suppl 3):S383-S389.
[cited by applicant]
Phillips et al., 2013, Interleukin-1 receptor antagonist deficient mice provide insights into pathogenesis of human intervertebral disc degeneration, Ann Rheum Dis, 72:1860-1867.
[cited by applicant]
Phillips et al., 2013, The cytokine and chemokine expression profile of nucleus pulposus cells: implications for degeneration and regeneration of the intervertebral disc, Arthritis Res Ther. 15:R213.
[cited by applicant]
Phillips et al., 2015, Potential roles of cytokines and chemokines in human intervertebral disc degeneration: interleukin-1 is a master regulator of catabolic processes, Osteoarthritis Cartilage, 23:1165-1177.
[cited by applicant]
Pockert et al., Feb. 2009, Modified expression of the ADAMTX enzymes and tissue inhibitor of metalloproteinases 3 during human intervertebral disc degeneration, Arthritis Rheum. 69(2):482-491.
[cited by applicant]
Pohl et al., Aug. 2016, Catabolic effects of endothelial cell-derived microparticles on disc cells: implications in intervertebral disc neovascularization and degeneration, pp. 1466-1474.
[cited by applicant]
Roberts et al., 2006, Senescence in human intervertebral discs, Eur Spine J. 15(Suppl. 3):S312-S316.
[cited by applicant]
Roberts et al., 2006, Topographical guidance of intervertebral disc cell growth in vitro: towards the development of tissue repair strategies for the anulus fibrosus, Eur Spine J. 15(Suppl. 3)S389-S396.
[cited by applicant]
Shamji et al., Jul. 2010, Proinflammatory cytokine expression profile in degenerated and herniated human intervertebral disc tissues, Arthritis Rheum. 62(7):1974-1982.
[cited by applicant]
Shankar et al., 2009, Anatomy and pathophysiology of intervertebral disc disease, Techniques in Regional Anesthesia and Pain Management, 13:67-75.
[cited by applicant]
Sheskey et al., Oct. 2020, Handbook of Pharmaceutical Excipients Ninth edition, TOC, 3 pp.
[cited by applicant]
Solovieva et al., 2004, Possible association of interleukin 1 gene locus polymorphisms with low back pain, Pain, 109:8-19.
[cited by applicant]
Solovieva et al., 2005, Intervertebral disc degeneration in relation to the COL9A3 and the IL-1? gene polymorphism, Eur Spine J. 15:613-618.
[cited by applicant]
Solovieva et al., Sep. 2004, Interleukin 1 polymorphisms and intervertebral disc degeneration, Epidemiology. 15(5):626-633.
[cited by applicant]
Suzuki et al., Jan. 2010, large-scale production of high-quality helper-dependent adenoviral vectors using adherent cells in cell factories, Human Gene Therapy, 21(1):120-126.
[cited by applicant]
The United States pharmacopeia, USP 30, The National formulary: NF 25, May 1, 2007 (TOC).
[cited by applicant]
Toietta et al., 2002, Generation of helper-dependent adenoviral vectors by homologous recombination. Mol Ther 5:204-210.
[cited by applicant]
Vo et al., Aug. 2016, Molecular mechanisms of biological aging in intervertebral discs, Orthop Res., pp. 1289-1306.
[cited by applicant]
International Search Report and Written Opinion dated Jan. 13, 2021 in application No. PCT/US20/51642.
[cited by applicant]
Abe et al., 2002, Enhancement of bone repair with a helper-dependent adenoviral transfer of bone morphogenetic protein-2, Biochemical and Biophysical Research Communications, 297(3):523-527.
[cited by applicant]
Accession No. NM_001082525.2 Equus caballus interleukin 1 receptor antagonist (IL1RN), mRNA, 2015, 3 pages.
[cited by applicant]
Accession No. NM_001082770 Oryctolagus cuniculus interleukin 1 receptor antagonist (ILIRN, mRNA 2011, 2 pages.
[cited by applicant]
Accession No. NM_174357.3, Bos taurus interleukin 1 receptor antagonist (IL1RN), mRNA, 2009, 2 pages.
[cited by applicant]
Adriaansen et al., 2006, Gene therapy as a therapeutic approach for the treatment of rheumatoid arthritis: innovative vectors and therapeutic genes, Rheumatology, 45:656-668.
[cited by applicant]
Backstrom et al., 2003, Recombinant MUC1 mucin with a breast cancer-like 0-glycosylation produced in large amounts in Chinese-hamsterovary cells, Biochem. J., 376:677-686.
[cited by applicant]
Bakker et al., Jun. 2002, C3-Tat/HIV-Regulated Intraarticular Human Interleukin-1 Receptor Antagonist Gene Therapy Results in Efficient Inhibition of Collagen-Induced Arthritis Superior to Cytomegalovirus-Regulated Expr…
[cited by applicant]
Bakker et al., 2001, A tropism-modified adenoviral vector increased the effectiveness of gene therapy for arthritis, Gene Therapy, 8(23):1785-1793.
[cited by applicant]
Bergelson et al., 1997, Isolation of a Common Receptor for Coxsackie B Viruses and Adenoviruses 2 and 5, Science, 275:1320-1323.
[cited by applicant]
Borzi et al., Aug. 2010, Matrix metalloproteinase 13 loss associated with impaired extracellular matrix remodeling disrupts Chondrocyte differentiation by concerted effects on multiple regulatory factors, Arthritis & Rh…
[cited by applicant]
Brunetti-Pierri et al., May 2011, Multi-Year Transgene expression in nonhuman primates following Hepatic transduction with helper-dependent adenoviral vectors, American Society of Gene & Cell Therapy, Annual Meeting 201…
[cited by applicant]
Brunetti-Pierri et al., 2004, Acute Toxicity After High-Dose Systemic Injection of Helper-Dependent Adenoviral Vectors into Nonhuman Primates, Human Gene Therapy, 15:35-46.
[cited by applicant]
Brunetti-Pierri et al., Aug. 2013, Transgene expression up to 7 years in nonhuman primates following hepatic transduction with helper-dependent adenoviral vectors, Human Gene Therapy, 24:1-5.
[cited by applicant]
Cao et al., 2011, The promotion of cartilage defect repair using adenovirus mediated Sox9 gene transfer of rabbit bone marrow mesenchymal stem cells, Biomaterials, 32:3910-3920.
[cited by applicant]
Caron et al., 2003, Principals and practices of joint disease treatment, In: Diagnosis and management of lameness in the horse, 1st Edition, Philadelphia: Saunders, pp. 746-764.
[cited by applicant]
Caron et al., Sep. 1996, Chondroprotective effect of intraarticular injections of interlukin-1 receptor antagonist in experimental osteoarthritis. Suppression of collagenase-1 expression., Arthritis Rheumatism, 39:9:153…
[cited by applicant]
Castello et al., Feb. 2016, Helper-dependent adenoviral vectors for liver-directed gene therapy of primary hyperoxaluria type 1 Gene Therapy, 23(2):129-134.
[cited by applicant]
Chen et al., Jan. 19, 2018, Sirt6 overexpression suppresses senescence and apoptosis of nucleus pulposus cells by inducing autophagy in a model of intervertebral disc degeneration, Cell Death & Disease, 9(2), 13 pp.
[cited by applicant]
Chen et al., Mar. 1997, Persistence in muscle of an adenoviral vector that lacks all viral genes, Proc. Natl. Acad. Sci. USA, 94:1645-1650.
[cited by applicant]
Chen et al., Oct. 16, 2021, SIRT6 inhibits endothelial-to-mesenchymal transition through attenuating the vascular endothelial inflammatory response, International Immunopharmacology 101(108240), 9 pp.
[cited by applicant]
Chen et al., Oct. 2010, Effects of adenovirus-mediated bFGF, IL-1Ra and IGF-1 gene transfer on human osteoarthritic chondrocytes and osteoarthritis in rabbits, Experimental and Molecular Medicine, 42(10):684-695.
[cited by applicant]
Coles et al., Jun. 2010, Loss of cartilage structure, stiffness, and frictional properties in mice lacking PRG4, Arthritis & Rheumatism, 62(6):1666-1674.
[cited by applicant]
Daheshia et al., 2008, The interleukin 1-beta pathway in the pathogenesis of osteoarthritis, The Journal of Rheumatology, 35(12):2306-2312.
[cited by applicant]
Daya et al., 2008, Gene Therapy Using Adeno-Associated Virus Vectors, Clin. Microbiol. Rev, 21(4):583-593.
[cited by applicant]
Dehne et al., 2009, Chondrogenic differentiation potential of osteoarthritic chondrocytes and their possible use in matrix-associated autologous chondrocyte transplantation, Arthritic Research and Therapy, 11(5):R133.
[cited by applicant]
Dinarello, 2003, Chapter 27-Interlukin-1 family, in The Cytokine Handbook, 4th Edition, 2:643-668.
[cited by applicant]
Dinser et al., 2001, Comparison of long-term transgene expression after non-viral and adenoviral gene transfer into primary articular chondrocytes, Histochemistry and Cell Biology 116:69-77.
[cited by applicant]
Dong et al., May 2023, Modulation of SIRT6 activity acts as an emerging therapeutic implication for pathological disorders in the skeletal system, Genes & Diseases, 10(3):864-876.
[cited by applicant]
Dormond et al., 2010, An efficient process for the purification of helper-dependent adenoviral vector and removal of helper virus by iodixanol ultracentrifugation, Journal of Virological Methods, 165:83-89.
[cited by applicant]
Dormond et al., Feb. 15, 2009, An Efficient and Scalable Process for Helper-Dependent Adenoviral Vector Production Using Polyethylenimine-Adenofection, Biotechnology and Bioengineering, 102(3):800-810.
[cited by applicant]
Echtermeyer et al., 2009, Syndecan-4 regulates ADAMTS-5 activation and cartilage breakdown in osteoarthritis, Nature Medicine, 15(9):1072-1077.
[cited by applicant]
Ehrke-Schulz et al., Jan. 28, 2016, Cloning and Large-Scale Production of High-Capacity Adenoviral Vectors Based on the Human Adenovirus Type 5, Journal of Visualized Experiments, 107:e52894, 15 pp.
[cited by applicant]
Evans et al., 1994,, Gene therapy for arthritis, Gene Therapeutics: Methods and Applications of direct Gene Transferm, Birkhauser: Boston, MA, pp. 320-343.
[cited by applicant]
Evans et al., 2004, Osteoarthritis gene therapy, Gene Therapy, Nature Publishing Group, 11:379-389.
[cited by applicant]
Evans et al., Jan. 1999, Gene Therapy for Rheumatic Diseases, Arthritis & Rheumatism, 42(1):1-16.
[cited by applicant]
Evans et al., Jan. 2018, Gene delivery to joints by intra-articular injection. Human Gene Therapy. 29(1):2-14.
[cited by applicant]
Flannery et al., Mar. 2009, Prevention of cartilage degeneration in a rat model of osteoarthritis by intraarticular treatment with recombinant lubricin, Arthritis & Rheumatism, 60(3):840-847.
[cited by applicant]
Flexion Press Release, Apr. 29, 2018, Flexion Therapeutics Announces Presentation of Positive FX201 Data at the Osteoarthritis Research Society International World Congress, 2 pp.
[cited by applicant]
Frisbie et al., 2002, Treatment of experimental equine osteoarthritis by in vivo delivery of the equine interleukin-1 receptor antagonist gene, Gene Therapy, 9:12-20.
[cited by applicant]
Fumoto et al., 2013, Targeted Gene Delivery: Importance of Administration Routes, Chapter 1 in Novel Gene Therapy Approaches, Intech, pp. 3-31.
[cited by applicant]
Ghivizzani et al., Apr. 1998, Direct adenovirus-mediated gene transfer of interleukin 1 and tumor necrosis factor a soluble receptors to rabbit knees with experimental arthritis has local and distal anti- arthritic effe…
[cited by applicant]
Giannoukakis et al., Sep. 1999, Adenoviral gene transfer of the interleukin-1 receptor antagonist protein to human islets prevents IL-1β-induced β-cell impairment and activation of islet cell apoptosis in vitro, Diabete…
[cited by applicant]
Glasson et al., 2020, The OARSI histopathology initiative—recommendations for histological assessments of osteoarthritis in the mouse, Osteoarthritic and Cartilage, 18:S17-S23.
[cited by applicant]
Goodrich et al., 2006, Direct adenovirus-mediated IGF-I gene transduction of synovium induces persisting synovial fluid IGF-I ligand elevations, Gene Therapy, 13:1253-1262.
[cited by applicant]
Goodrich et al., 2009, Ex Vivo Serotype-Specific Transduction of Equine Joint Tissue by Self-Complementary Adeno-Associated Viral Vectors, Human Gene Therapy, 20:1697-1702.
[cited by applicant]
Goodrich et al., 2015, scAAVIL-Ira dosing trial in a large animal model and validation of long-term expression with repeat administration for osteoarthritis therapy, Gene Therapy, 22(7):536-545.
[cited by applicant]
Goodrich et al.. , 2013, Optimization of scAAVIL-Ira In Vitro and In Vivo to Deliver High Levels of Therapeutic Protein for Treatment of Osteoarthritis, Molecular Therapy Nucleic Acids, 5(2):e70, 10 pp.
[cited by applicant]
Goossens et al., 2001, Infection Efficiency of Type 5 Adenoviral Vectors in Synovial Tissue Can Be Enhanced With a Type 16 Fiber, Arthritis & Rheumatism, 44(3):570-577.
[cited by applicant]
Goossens et al., 2001, The Influence of Synovial Fluid on Adenovirus-Mediated Gene Transfer to the Synovial Tissue, Arthritis & Rheumatism,. 44(1):48-52.
[cited by applicant]
Goupille et al., 2007, Is interleukin-1 a good target for therapeutic intervention in intervertebral disc degeneration: lessons from the osteoarthritic experience, Arthritis Res Ther, 9(6):110.
[cited by applicant]
Grol et al., Apr. 26-29, 2018, Interleukin-1 Receptor Antagonist Gene Therapy Prevents and Delays Surgically-Induced Osteoarthritis in Small and Large Animal Models, 2018 World Congress of Osteoarthritis, 26 pp.
[cited by applicant]
Harui et al., Jul. 1999, Frequency and Stability of Chromosomal Integration of Adenovirus Vectors, Journal of Virology, 73(7):6141-6146.
[cited by applicant]
Horwood et al., 2002, High-efficiency gene transfer into nontransformed cells: utility for studying gene regulation and analysis of potential therapeutic targets, Arthritis Research, 4(Suppl. 3):S215-S225.
[cited by applicant]
Ishihara et al., 2012, Inflammation and Immune Response of Intra-Articular Serotype 2 Adeno-Associated Virus or Adenovirus Vectors in a Large Animal Model, Arthritis, vol. 2012, Article ID: 735472, 8 pages.
[cited by applicant]
Jay et al., 2007, The role of lubricin in the mechanical behavior of synovial fluid, PNAS, 104(15):6194-6199.
[cited by applicant]
Jerebtsova et al., A Simple Technique to Establish a Long-Term Adenovirus Mediated Gene Transfer to the Heart of Newborn Mice, Cardiovasc Hematol Disord Drug Targets. Jun. 2009; 9(2): 136-140.
[cited by applicant]
Johnson et al., Mar. 11, 2012, A stem cell-based approach to cartilage repair, Science, 336:717-721.
[cited by applicant]
Kaditis et al., Mar. 14, 2007, Anti-inflammatory pharmacotherapy for wheezing in preschool children, Pediatric Pulmonology, 42(5):407-420.
[cited by applicant]
Kang et al., Mar. 2017, Sirtuin 6 prevents matrix degradation through inhibition of the NF-[kappa]B pathway in intervertebral disc degeneration, Experimental Cell Research, 352(2):322-332.
[cited by applicant]
Kay et al., Jul. 2009, Intra-articular gene delivery and expression of interleukin-1 Ra mediated by self-complementary adenoassociated virus, The Journal of Gene Medicine, 11:605-614.
[cited by applicant]
Khoury, Jul. 2007, Inflammation-inducible anti-TNF gene expression mediated by intra-articular injection of serotype 5 adeno-associated virus reduces arthritis, The Journal of Gene Medicine, 9(7):596-604.
[cited by applicant]
Kochanek, Oct. 10, 1999, High-capacity adenoviral vectors for gene transfer and somatic gene therapy, Human Gene Therapy, 10:2451-2459.
[cited by applicant]
Le Maitre et al., 2007, Interleukin-1 receptor antagonist delivered directly and by gene therapy inhibits matrix degradation in the intact degenerate human intervertebral disc: an in situ zymographic and gene therapy st…
[cited by applicant]
Lee et al., 2017, Adenovirus-mediated gene delivery: potential applications for gene and cell-based therapies in the new era of personalized medicine, Genes & Diseases, 4:43-63.
[cited by applicant]
Lee et al., Oct. 2019, No more helper adenovirus: production of gutless adenovirus (GLAd) free of adenovirus and replication-competent adenovirus (RCA) contaminants, Experimental & Molecular Medicine, S1:127 and supplem…
[cited by applicant]
Lin et al., Jun. 16, 2003, Enhancing adenovirus-mediated gene transfer in vitro and in vivo by addition of protamine and hydrocortisone, The Journal of Gene Medicine, 5(10):868-875.
[cited by applicant]
Lopez Castel et al., Mar. 2010, Repeat instability as the basis for human diseases and as a potential target for therapy, Mol. Cell Biol., 11:165-170.
[cited by applicant]
Makino et al., 2001, Inhibitory PAS domain protein is a negative regulator of hypoxia-inducible gene expression, Nature, 389(6863):550-554.
[cited by applicant]
Manno et al., Apr. 15, 2003, AAV-mediated factor IX gene transfer to skeletal muscle in patients with severe hemophilia B, Blood, 101(8):2963-2972.
[cited by applicant]
Marcelino et al., CACP, encoding a secreted proteoglycan, is mutated in camptodactyly-arthropathy-coxa vara pericarditis syndrome, Nature Genetics, 23:319-322.
[cited by applicant]
Mingozzi et al., 2007, CD8+ T-cell responses to adeno associated virus capsid in humans, Nature Medicine, 13(4):419-422.
[cited by applicant]
Mitani et al., Apr. 1995, Rescue, propagation, and partial purification of a helper virus-dependent adenovirus vector, Proc. Natl. Acad. Sci. USA, 92:3854-3858.
[cited by applicant]
Morral et al., 2002, Lethal Toxicity, Severe Endothelial Injury, and a Threshold Effect with High Doses of an Adenoviral Vector in Baboons, Human Gene Therapy, 13:143-154.
[cited by applicant]
Muruve et al., 2004, Helper-Dependent Adenovirus Vectors Elicit Intact Innate but Attenuated Adaptive Host Immune Responses In Vivo, Journal of Virology, 78(11):5966-5972.
[cited by applicant]
Nakao et al., 1997, Identification of SMAD7, a TGFbeta-inducible antagonist of TGF-beta signalling, Nature, 389(6651):631-635.
[cited by applicant]
Nathwani et al., Dec. 22, 2011, Adenovirus-associated virus vector-mediated gene transfer in Hemophilia B, N. Engl. J. Med., 365(25):2357-2365.
[cited by applicant]
NCT00126724 Study of Intra-articular Delivery of tgAAC94 in Inflammatory Arthritis Subjects, 11 pages, 2005.
[cited by applicant]
NCT00617032 Phase 1 Dose Escalation Study of Intra-Articular Administration of tgAAC94, 8 pages, 2008.
[cited by applicant]
NCT02790723 Safety of Intra-Articular Sc-rAAV2.51L-1Ra in Subjects With Moderate Knee Oa (AAVIL-1Ra), 2016.
[cited by applicant]
Nixon et al., Nov. 2018, Disease-modifying osteoarthritis treatment with interleukin-1 receptor antagonist gene therapy in small and large animal models, Arthritis Rheumatol, 70(11):1757-1768.
[cited by applicant]
Ogawa et al., 2013, Mechanical motion promotes expression of Prg4 in articular cartilage via multiple GREB-dependent, fluid flow shear stress-induced signaling pathways, Genes & Development, 28:127-139.
[cited by applicant]
Oren et al., Short tandem repeats, segmental duplications, gene deletion, and genomic instability in a rapidly diversified immune gene family, BMC Genomics, 17:900-919 (2016).
[cited by applicant]
Pacira Biosciences, Better is Possible. EXP22000162, PowerPoint presentation, 5 pp.
[cited by applicant]
Palmer et al., 2005, Helper-Dependent Adenoviral Vectors for Gene Therapy, Human Gene Therapy, 16:1-16.
[cited by applicant]
Pano et al., 2023, A scalable, suspension-based platform to produce virus-like particles (VLPs) for in vivo gene therapy, Ensoma conference poster, 1 p.
[cited by applicant]
Parks et al., Nov. 1996, A helper-dependent adenovirus vector system: Removal of helper virus by Cre-mediated excision of the viral packaging signal, Proc. Natl. Acad. Sci. USA, 92:13565-13570.
[cited by applicant]
Parks, 2000, Improvements in adenoviral vector technology: overcoming barriers for gene therapy, Clinical Genetics, 58:1-11.
[cited by applicant]
Paul et al., Apr. 15, 2003, Potential use of Sox9 gene therapy for intervertebral degenerative disc disease, Spine, 28(8):755-763.
[cited by applicant]
Paz-Gonzalez et al., 2023 An Atlas of the Knee Joint Proteins and Their Role in Osteoarthritis Defined by Literature Mining, Mol Cell Proteomics, 22(8):100606.
[cited by applicant]
Pearson et al., Repeat instability: mechanisms of dynamic mutations, Genetics, 6:729-742 (Oct. 2005).
[cited by applicant]
Pritzker et al., 2006, Osteoarthritis cartilage histopathology: grading and staging, Osteoarthritis and Cartilige, 14(1):13-29.
[cited by applicant]
Rhee et al., 2005, The secreted glycoprotein lubricin protects cartilage surfaces and inhibits synovial cell overgrowth, The Journal of Clinical Investigation, 115(3):622-631.
[cited by applicant]
Roessler et al., Mar. 1995, Inhibition of Interleukin-1-Induced Effects in Synoviocytes Trans duce d with the Human IL-1 Receptor Antagonist cDNA Using an Adenoviral Vector, Human Gene Therapy, 6:307-316.
[cited by applicant]
Ross et al., Sep. 2009, Host Cell Detection of Noncoding Stuffer DNA Contained in Helper- Dependent Adenovirus Vectors Leads to Epigenetic Repression of Transgene Expression. Journal of Virology, 83(17):8409-8417.
[cited by applicant]
Ruan et al., 2013, Proteoglycan 4 Expression Protects Against the Development of Osteoarthritis, Science Translational Medicine, 5(176):176ra34, 26 pp.
[cited by applicant]
Ruan et al., 2016, Treatment of osteoarthritis using a helper-dependent adenoviral vector retargeted to chondrocytes, Molecular Therapy Methods & Clinical Development, 3:16008.
[cited by applicant]
Ruan et al., Feb. 2013, Quantitative imaging of murine osteoarthritic cartilage by phase contrast micro-computed tomography, Arthritis Rheumatism, 65:2:388-396.
[cited by applicant]
Ruan, Jan. 2013, Prevention of osteoarthritis by combination of prteoglycan 4 and interleukin 1 receptor antagonist expression, ASBMR 2013 Annual meeting, S200, https://www/asbmr.org/meetings/2013-abstracts.
[cited by applicant]
Saito et al., Jun. 2010, Transcriptional regulation of endochondral ossification by HIF-2alpha during skeletal growth and osteoarthritis development, Nature Medicine, 16(6):678-687.
[cited by applicant]
Sampara et al., 2018, Understanding the molecular biology of intervertebral disc degeneration and potential gene therapy strategies for regeneration: a review, Gene Therapy, 25:67-82.
[cited by applicant]
Sandig et al., Feb. 1, 2000, Optimization of the helper-dependent adenovirus system for production and potency in vivo, PNAS, 97(3):1002-1007.
[cited by applicant]
Santangelo et al., 2010, Detectable Reporter Gene Expression following Transduction of Adenovirus and Adeno-Associated Virus Serotype 2 Vectors within Full-Thickness Osteoarthritic and Unaffected Canine Cartilage In Vit…
[cited by applicant]
Schmidt et al., 2009, Disulfide-bonded multimers of proteoglycan 4 (PRG4) are present in normal synovial fluids, Biochimica et Biophysica Acta, 1790:375-384.
[cited by applicant]
Smith et al., Sep. 11, 1998 Secretory Interleukin-1 Receptor Antagonist Gene Expression Requires both a PU.1 and a Novel Composite NF-kB/PU.1/GA-binding Protein Binding Site, JBC, 273(37):24272-24279.
[cited by applicant]
Stone et al., 2019, Combinatorial Prg4 and 11-1 ra Gene Therapy Protects Against Hyperalgesia and Cartilage Degeneration in Post-Traumatic Osteoarthritis, Human gene therapy, 30(2):225-235.
[cited by applicant]
Suzuki et al., 2010, MyD88-Dependent Silencing of Transgene Expression During the Innate and Adaptive Immune Response to Helper-Dependent Adenovirus, Human Gene Therapy, 21:325-336.
[cited by applicant]
Takahata et al., 2022, Regulatory Mechanisms of Prg4 and Gdf5 Expression in Articular Cartilage and Functions in Osteoarthritis, Int. J. Mol. Sci., 23:4672.
[cited by applicant]
Tellez et al., 2005, Adenoviral overexpression of interleukin-1 receptor antagonist protein increases β-cell replication in rat pancreatic islets, Gene Therapy, 12:120-128.
[cited by applicant]
Toh et al., 2005, Enhancement of Adenovirus-Mediated Gene Delivery to Rheumatoid Arthritis Synoviocytes and Synovium by Fiber Modifications: Role of Arginine-Glycine-Aspartic Acid (RGD)-and Non-RGD-Binding Integrins, Jo…
[cited by applicant]
Ulrich-Vintner et al., 2004, In vivo gene delivery to articular chondrocytes mediated by an adeno- associated virus vector, Journal of Orthopedic Research, 22:726-734.
[cited by applicant]
Vetrini et al., 2010,, Gene Therapy with Helper-Dependent Adenoviral Vectors: Current Advances and Future Perspectives. Viruses 2:1886-1917.
[cited by applicant]
Wang et al., 2006, Adenovirus expressing niterleukin-1 receptor antagonist alleviates allergic airway inflammation in a murine model of asthma, Gene Therapy, 13:1414-1421.
[cited by applicant]
White et al., 2007, Gene therapy for hemophilia A, Textbook of Hemophilia, Chapter 39, 4 pp.
[cited by applicant]
Willet et al., 2013, Immunology of AAV-mediated gene transfer in the eye, Frontiers in Immunology, 4(Article 261), 8 pp.
[cited by applicant]
Xie et al., Sep. 29, 2020, Sirtuin 6: A potential therapeutic target for cardiovascular diseases, Pharmacological Research, 163(105214), 10 pp.
[cited by applicant]
Yang et al., 1997, Overexpression of interleukin-1 receptor antagonist in the mouse brain reduces ischemic brain injury, Brain Research, 751:181-188.
[cited by applicant]
Yeh et a., 1997, Advances in adenoviral vectors: from genetic engineering to their biology, FASEB Journal, 11(8):615-623.
[cited by applicant]